Abstract
Introduction
Patient-reported outcome measures (PROs) exist for psoriasis but not genital psoriasis (GenPs).
Methods
This cross-sectional, qualitative study in patients with moderate-to-severe GenPs was conducted to support development of a PRO for measuring the impact of GenPs on sexual activity and to establish content validity. The impacts of GenPs were identified in a literature review. Findings from the literature review were discussed with clinicians, and then patients with GenPs were interviewed.
Results
From the literature review, 52 articles, 44 abstracts, and 41 clinical trials met predefined search criteria. Of these, 11 concepts emerged as having theoretical support for use as measurable impacts of psoriasis symptoms on patients; these concepts included sexual functioning and general health-related quality of life (HRQoL). These concepts were confirmed and expanded upon by two clinicians who routinely care for patients with GenPs. Interviews were then conducted with GenPs patients (n = 20) to discuss the impact of GenPs on their HRQoL. Eighty percent of patients reported that GenPs impacted sexual frequency. The two-item GenPs Sexual Frequency Questionnaire (GenPs-SFQ) was developed to assess limitations on sexual activity frequency because of GenPs. Cognitive debriefing with an additional 50 patients with GenPs confirmed the utility and understandability of the GenPs-SFQ.
Conclusion
The GenPs-SFQ may have utility in clinical trials involving GenPs patients and in routine clinical practice.
Funding
Eli Lilly and Company.
Plain Language Summary
Plain language summary available for this article.
http://ift.tt/2kmb4LT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου